Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
Convenience and tolerability benefits could position aztreonam lysine as best-in-class.
You may also be interested in...
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
Gilead Hopes To Dodge New Trial With Cystic Fibrosis Antibiotic
Complete response letter for Cayston (aztreonam) requests another study, but Gilead is talking with FDA to see if re-analysis of existing data will suffice